{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:09:07Z","timestamp":1777356547384,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1023\/a:1012836331506","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T10:09:07Z","timestamp":1040638147000},"page":"251-256","source":"Crossref","is-referenced-by-count":26,"title":["Pergolide As Primary Therapy for Macroprolactinomas"],"prefix":"10.1007","volume":"3","author":[{"given":"John J.","family":"Orrego","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel L.","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"382165_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-200059010-00006","volume":"59","author":"JJ Orrego","year":"2000","unstructured":"Orrego JJ, Barkan AL. Pituitary disorders. Drug treatment options. Drugs 2000;59:93\u2013106.","journal-title":"Drugs"},{"key":"382165_CR2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220\u2013240.","journal-title":"Endocr Rev"},{"key":"382165_CR3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-8529(05)70061-X","volume":"28","author":"ME. Molitch","year":"1999","unstructured":"Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143\u2013169.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"382165_CR4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0889-8529(18)30193-2","volume":"21","author":"ME. Molitch","year":"1992","unstructured":"Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992;21:877\u2013901.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"382165_CR5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group [see comments]. N Engl J Med 1994;331:904\u2013909.","journal-title":"N Engl J Med"},{"key":"382165_CR6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","volume":"46","author":"CI Ferrari","year":"1997","unstructured":"Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: A study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409\u2013413.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"382165_CR7","first-page":"2338","volume":"81","author":"BM Biller","year":"1996","unstructured":"Biller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81: 2338\u20132343.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR8","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Landi ML, et al. Long-term and lowdose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574\u20133579.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1009913200542","volume":"2","author":"N. K. Pontikides","year":"2000","unstructured":"Pontikides N KG, Nikopoulou E, Kaltsas T. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary 2000;2:277\u20132781.","journal-title":"Pituitary"},{"key":"382165_CR10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.382359","volume":"205","author":"L Lemberger","year":"1979","unstructured":"Lemberger L, Crabtree RE. Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science 1979;205:1151\u20131153.","journal-title":"Science"},{"key":"382165_CR11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(81)90997-1","volume":"2","author":"S Franks","year":"1981","unstructured":"Franks S, Horrocks PM, Lynch SS, Butt WR, London DR. Treatment of hyperprolactinaemia with pergolide mesylate: Acute effects and preliminary evaluation of long-term treatment. Lancet 1981;2:659\u2013661.","journal-title":"Lancet"},{"key":"382165_CR12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bmj.285.6340.465","volume":"285","author":"P Kendall-Taylor","year":"1982","unstructured":"Kendall-Taylor P, Hall K, Johnston DG, Prescott RW. Reduction in size of prolactin-secreting tumours in men treated with pergolide. Br Med J (Clin Res Ed) 1982;285:465\u2013467.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"382165_CR13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0015-0282(16)47111-6","volume":"39","author":"RE Blackwell","year":"1983","unstructured":"Blackwell RE, Bradley EL, Jr., Kline LB, et al. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: A multicenter study. Fertil Steril 1983;39: 744\u2013748.","journal-title":"Fertil Steril"},{"key":"382165_CR14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM198309223091205","volume":"309","author":"DL Kleinberg","year":"1983","unstructured":"Kleinberg DL, Boyd AEd, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704\u2013709.","journal-title":"N Engl J Med"},{"key":"382165_CR15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0002-9378(86)90685-X","volume":"154","author":"OA Kletzky","year":"1986","unstructured":"Kletzky OA, Borenstein R, Mileikowsky GN. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia. Am J Obstet Gynecol 1986;154:431\u2013435.","journal-title":"Am J Obstet Gynecol"},{"key":"382165_CR16","first-page":"375","volume":"27","author":"M Berezin","year":"1991","unstructured":"Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991; 27:375\u2013379.","journal-title":"Isr J Med Sci"},{"key":"382165_CR17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/jcem-72-3-635","volume":"72","author":"SW Lamberts","year":"1991","unstructured":"Lamberts SW, Quik RF. A comparison of the ef~cacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991;72:635\u2013641.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1210\/jcem.85.1.6329","volume":"85","author":"PU Freda","year":"2000","unstructured":"Freda PU, Andreadis CI, Khandji AG, et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR19","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients [see comments]. J Clin Endocrinol Metab 1999;84:2518\u20132522.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR20","first-page":"489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol(Copenh) 1992;126:489\u2013494.","journal-title":"Acta Endocrinol(Copenh)"},{"key":"382165_CR21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698\u2013705.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1380286","volume":"138","author":"M De Rosa","year":"1998","unstructured":"De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine. Eur J Endocrinol 1998;138:286\u2013293.","journal-title":"Eur J Endocrinol"},{"key":"382165_CR23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1210\/jcem-53-4-772","volume":"53","author":"RL Perryman","year":"1981","unstructured":"Perryman RL, Rogol AD, Kaiser DL, MacLeod RM, Thorner MO. Pergolide mesylate: Its effects on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab 1981;53:772\u2013778.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1210\/jcem-52-4-650","volume":"52","author":"WH Martin","year":"1981","unstructured":"Martin WH, Rogol AD, Kaiser DL, Thorner MO. Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. J Clin Endocrinol Metab 1981;52:650\u2013656.","journal-title":"J Clin Endocrinol Metab"},{"key":"382165_CR25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198505233122106","volume":"312","author":"ME. Molitch","year":"1985","unstructured":"Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1364\u20131370.","journal-title":"N Engl J Med"},{"key":"382165_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","volume":"10","author":"E Robert","year":"1996","unstructured":"Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative cabergoline. Reprod Toxicol 1996;10:333\u2013337.","journal-title":"Reprod Toxicol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1012836331506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1012836331506\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1012836331506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T05:01:09Z","timestamp":1754283669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1012836331506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["382165"],"URL":"https:\/\/doi.org\/10.1023\/a:1012836331506","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}